Eli Lilly and Company, Moderna, and Johnson & Johnson are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies that develop, manufacture, or provide healthcare products and services, including pharmaceuticals, medical devices, biotechnology, hospitals, and health insurance. For investors, they offer exposure to the healthcare sector, whose performance can be influenced by factors such as medical innovation, regulation, and demand for care. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
LLY traded up $17.12 during trading on Friday, reaching $1,444.40. 795,689 shares of the company traded hands, compared to its average volume of 2,951,607. The company has a market cap of $1.36 trillion, a P/E ratio of 46.88, a PEG ratio of 1.72 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,460.00. The firm has a fifty day simple moving average of $1,236.58 and a 200 day simple moving average of $1,108.27.
Read Our Latest Research Report on LLY
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
MRNA traded down $6.73 during trading on Friday, hitting $224.62. 3,822,242 shares of the company traded hands, compared to its average volume of 12,554,390. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The company has a market cap of $90.89 billion, a PE ratio of -31.77 and a beta of 1.16. The stock's 50-day simple moving average is $200.18 and its two-hundred day simple moving average is $95.52. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80.
Read Our Latest Research Report on MRNA
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
JNJ stock traded up $2.79 during mid-day trading on Friday, hitting $286.31. The company had a trading volume of 2,182,743 shares, compared to its average volume of 7,933,827. The company has a 50-day moving average price of $266.83 and a 200 day moving average price of $249.54. Johnson & Johnson has a 12-month low of $193.55 and a 12-month high of $288.11. The company has a market capitalization of $689.22 billion, a price-to-earnings ratio of 43.41, a P/E/G ratio of 2.77 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Read Our Latest Research Report on JNJ
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
